Physician profile
Christopher Berry
NPI 1770086324
$1,880.15
in general payments reported to CMS, 2019-2025
14 companies · $20.51 in 2025
The $20.51 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $677 · 2022: $566 · 2023: $443 · 2024: $173 · 2025: $20.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $579.45 | 2021-2024 | Xarelto |
| Pfizer INC. | $344.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $296.92 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $185.75 | 2022-2024 | Soliris, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $145.40 | 2021-2024 | Eliquis |
| Gilead Sciences, INC. | $121.98 | 2022-2023 | Veklury |
| Abbvie INC. | $59.94 | 2021-2022 | |
| Boston Scientific Corporation | $39.60 | 2021 | |
| Inari Medical, INC. | $22.18 | 2021 | |
| Melinta Therapeutics, LLC | $20.56 | 2022 | |
| Vifor Pharma, INC. | $18.72 | 2021 | |
| Merck Sharp & Dohme LLC | $17.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.74 | 2022 | |
| Cvrx, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.